Almotriptan, a
serotonin 5-HT 1B/1D agonist, was developed for the acute treatment of
migraine with or without
aura and has been available for 10 years. This article evaluates the wealth of experience that has been obtained with
almotriptan, including large randomized clinical trials (RCTs) and post-marketing studies that more closely reflect everyday clinical practice. Initial RCTs required patients to take
almotriptan when
migraine pain was of moderate or severe intensity, and found that 12.5 mg provided optimal outcomes for both
pain relief and tolerability.
Almotriptan effectively improved 2-h
pain-relief, reduced
migraine-associated symptoms and demonstrated low recurrence rates. These findings were also shown in patient subgroups, such as adolescents and menstrual migraineurs. A secondary finding in these trials was that patients who took
almotriptan early, when the
pain was still mild, achieved better outcomes. This prompted the initiation of studies designed to assess the effect of
almotriptan in early intervention. Open-label trials reported improvements in
pain-free end points (2 h, 24 h), and subsequent RCTs confirmed these findings. Pharmacovigilance data from more than 100 million
tablets dispensed worldwide have confirmed that
almotriptan is associated with a low occurrence of adverse effects, which, in clinical trials, has been shown to be similar to that observed with placebo. The clinical evidence obtained and comparisons made over a decade of use have demonstrated that
almotriptan is one of the more effective and fast-acting
triptans available, with a placebo-like tolerability profile. This suggests that
almotriptan is an excellent choice for patients requiring specific acute
migraine treatment.